 <h1>Protonix Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>pantoprazole</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about pantoprazole. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Protonix.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> diarrhea and nausea.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pantoprazole: oral packet, oral tablet enteric coated</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pantoprazole (the active ingredient contained in Protonix) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking pantoprazole:</p><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>dry mouth</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>nausea</li>
<li>stomach pain</li>
<li>sweating</li>
<li>troubled breathing</li>
<li>unexplained weight loss</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Absence of or decrease in body movements</li>
<li>blindness</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>bloody or cloudy urine</li>
<li>bloody, black, or tarry stools</li>
<li>blurred vision</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>constipation</li>
<li>continuous ringing or buzzing or other unexplained noise in the ears</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased vision</li>
<li>diarrhea</li>
<li>difficulty with speaking</li>
<li>difficulty with swallowing</li>
<li>dizziness or lightheadedness</li>
<li>drowsiness</li>
<li>fast heartbeat</li>
<li>feeling of constant movement of self or surroundings</li>
<li>fever</li>
<li>general feeling of tiredness or weakness</li>
<li>greatly decreased frequency of urination or amount of urine</li>
<li>headache</li>
<li>hearing loss</li>
<li>high fever</li>
<li>hives, itching, or skin rash</li>
<li>indigestion</li>
<li>joint pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>mood or mental changes</li>
<li>muscle cramp, pain, or stiffness</li>
<li>muscle spasms (tetany) or twitching</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>pale skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>sensation of spinning</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stomach pain, continuing</li>
<li>swelling of the feet or lower legs</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>trembling</li>
<li>unexplained bleeding or bruising</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pantoprazole may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Belching</li>
<li>bloated or full feeling</li>
<li>excess air or gas in the stomach or bowels</li>
<li>passing gas</li>
<li>trouble sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Increased watering of the mouth</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pantoprazole: intravenous powder for injection, oral delayed release tablet, oral granule enteric coated</i></p><h3>General</h3><p>The most commonly reported side effects were headache, diarrhea, and injection site thrombophlebitis (in IV formulations).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (Up to 26.4%), taste pervasion (Up to 18.2%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, metallic/bitter taste, somnolence</p>
<p><b>Rare</b> (0.01% to 0.1%): Taste disorders</p>
<p><b>Very rare</b> (less than 0.01%): Change to the sense of taste, reduced movement, speech disorder</p>
<p><b>Frequency not reported</b>: Paresthesia, vertigo</p>
<p><b>Postmarketing reports</b>: Ageusia, dysgeusia<sup>[Ref]</sup></p><p>Headache was a very commonly reported side effect in pediatric patients 2 to 16 years of age.  In adults, headache occurred most frequently in patients given quadruple therapy (pantoprazole, bismuth, metronidazole, tetracycline) for H pylori infections, but was also very common in triple therapy (pantoprazole, amoxicillin, clarithromycin).</p>
<p></p>
<p>Taste pervasion most frequently occurred in patients given triple therapy, but it was also very common in patients given quadruple therapy.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Nasopharyngitis and pharyngolaryngeal pain occurred in pediatric patients between the ages of 2 to 16 years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nasopharyngitis (up to 13.6%), pharyngolaryngeal pain (up to 13.2%)</p>
<p><b>Common</b> (1% to 10%): Cough, nasal congestion, pharyngitis</p>
<p><b>Very rare</b> (less than 0.01%): Change to the sense of smell, dyspnea</p>
<p><b>Frequency not reported</b>: Upper respiratory tract infection<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Diarrhea occurred most frequently in patients given quadruple therapy (pantoprazole (the active ingredient contained in Protonix)  bismuth, metronidazole, tetracycline) for Helicobacter pylori infections, but was also very common in triple therapy (pantoprazole, amoxicillin, clarithromycin).</p>
<p></p>
<p>Nausea, vomiting, abdominal pain, dry mouth, and constipation were more commonly reported in patients given triple therapy, compared to patients given quadruple therapy.</p>
<p></p>
<p>Fecal and/or tongue discoloration occurred more commonly in patients given quadruple therapy versus patients given triple therapy.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Diarrhea (Up to 11.6%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, benign fundic gland polyps/fundic gland polyps, buccal inflammation, constipation, dry mouth, dyspepsia, fecal discoloration, flatulence, heartburn, nausea, oral moniliasis, pruritus ani, tongue discoloration, tongue pain, upper abdominal pain, vomiting</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal discomfort/distention, bloating, loose stools</p>
<p><b>Rare</b> (0.01% to 0.1%): Colon polyp, rectal disorder</p>
<p><b>Very rare</b> (less than 0.01%): Increased saliva</p>
<p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea, severe eructation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Tiredness</p>
<p><b>Uncommon</b> (0.1% to 1%): Asthenia, fatigue, malaise</p>
<p><b>Rare</b> (0.01% to 0.1%): Body temperature increased, fever</p>
<p><b>Very rare</b> (less than 0.01%): Pain, tinnitus</p>
<p><b>Frequency not reported</b>: Facial edema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Confusion, depression, hallucinations, and disorientation, especially in predisposed patients, occurred with use, and was aggravated in patients with preexisting conditions.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Depression (and all aggravations)</p>
<p><b>Uncommon</b> (0.1% to 1%): Sleep disorders</p>
<p><b>Rare</b> (0.01% to 0.1%): Confusion (and all aggravations), disorientation (and all aggravations), hallucination (and all aggravations)</p>
<p><b>Very rare</b> (less than 0.01%): Anxiety</p>
<p><b>Postmarketing reports</b>: Insomnia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased liver enzymes (transaminases, GGT)</p>
<p><b>Rare</b> (0.01% to 0.1%): Increased bilirubin</p>
<p><b>Very rare</b> (less than 0.01%): Cholestatic hepatitis, hepatitis, hepatocellular failure, jaundice</p>
<p><b>Frequency not reported</b>: Hepatic effects, hepatocellular injury, liver function tests abnormal</p>
<p><b>Postmarketing reports</b>: Hepatocellular damage<sup>[Ref]</sup></p><p>Severe hepatocellular damage leading to jaundice/hepatic failure is predicted to have a frequency of 1 in 1,000,000 patients.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Exanthema/exanthemata, rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Eruption, increased sweating, pruritus</p>
<p><b>Rare</b> (0.01% to 0.1%): Urticaria</p>
<p><b>Very rare</b> (less than 0.01%): Erythema multiforme, flushing, Lyell syndrome, photosensitivity/photosensitivity reaction, severe skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p>
<p><b>Frequency not reported</b>: Cutaneous lupus erythematosus, facial edema, fatal skin reactions, fatal TEN, subacute cutaneous lupus erythematosus<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Rare</b> (0.01% to 0.1%): Hypertension, peripheral edema, thrombophlebitis</p>
<p><b>Very rare</b> (less than 0.01%): Circulatory collapse, flushing, hot flushes, substernal chest pain</p>
<p><b>Frequency not reported</b>: Generalized edema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Muscle spasm occurred as a consequence of electrolyte disturbances.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Arthralgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Fracture of the hip/wrist/spine</p>
<p><b>Rare</b> (0.01% to 0.1%): Myalgia</p>
<p><b>Very rare</b> (less than 0.01%): Skeletal pain</p>
<p><b>Frequency not reported</b>: Bone fracture, elevated creatine phosphokinase (CPK)/elevated creatine kinase (CK), muscle spasm, systemic lupus erythematosus</p>
<p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p>
<p><b>Rare</b> (0.01% to 0.1%): Hyperlipidemia, increased cholesterol, increased triglycerides, lipid increases, weight changes</p>
<p><b>Frequency not reported</b>: Cyanocobalamin (vitamin B12) deficiency), electrolyte disturbances, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, potential for exacerbation of zinc deficiency<sup>[Ref]</sup></p><p>Hypocalcemia occurred in association with hypomagnesemia.</p>
<p></p>
<p>Anorexia commonly occurred in patients with H pylori.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site thrombophlebitis</p>
<p><b>Frequency not reported</b>: Injection site reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza-like symptoms, moniliasis</p>
<p><b>Rare</b> (0.01% to 0.1%): Sepsis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions, anaphylactic shock, angioedema/Quincke's edema, hypersensitivity, hypersensitivity reactions</p>
<p><b>Frequency not reported</b>: Allergic reactions</p>
<p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, anemia</p>
<p><b>Very rare</b> (less than 0.01%): Increased coagulation time, leukopenia, pancytopenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Blurred vision, visual disturbances</p>
<p><b>Very rare</b> (less than 0.01%): Conjunctivitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (0.01% to 0.1%): Gynecomastia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Interstitial nephritis (with possible progression to renal failure)</p>
<p><b>Frequency not reported</b>: Acute interstitial nephritis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Protonix I.V. (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. Protonix (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Protonix (pantoprazole)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>74 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: proton pump inhibitors</li>
<li>FDA Alerts (4)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Protonix oral/injection</li>
<li>Protonix &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Protonix Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Protonix IV</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>GERD</li>
<li>Erosive Esophagitis</li>
<li>Barrett's Esophagus</li>
<li>Duodenal Ulcer</li>
<li data-more-config-id="list-data-resources-conditions">... +5 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pantoprazole: intravenous powder for injection, oral delayed release tablet, oral granule enteric coated</i></p><h3>General</h3><p>The most commonly reported side effects were headache, diarrhea, and injection site thrombophlebitis (in IV formulations).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (Up to 26.4%), taste pervasion (Up to 18.2%)</p><p><b>Common</b> (1% to 10%): Dizziness, metallic/bitter taste, somnolence</p><p><b>Rare</b> (0.01% to 0.1%): Taste disorders</p><p><b>Very rare</b> (less than 0.01%): Change to the sense of taste, reduced movement, speech disorder</p><p><b>Frequency not reported</b>: Paresthesia, vertigo</p><p><b>Postmarketing reports</b>: Ageusia, dysgeusia<sup>[Ref]</sup></p><p>Headache was a very commonly reported side effect in pediatric patients 2 to 16 years of age.  In adults, headache occurred most frequently in patients given quadruple therapy (pantoprazole, bismuth, metronidazole, tetracycline) for H pylori infections, but was also very common in triple therapy (pantoprazole, amoxicillin, clarithromycin).</p><p></p><p>Taste pervasion most frequently occurred in patients given triple therapy, but it was also very common in patients given quadruple therapy.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Nasopharyngitis and pharyngolaryngeal pain occurred in pediatric patients between the ages of 2 to 16 years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nasopharyngitis (up to 13.6%), pharyngolaryngeal pain (up to 13.2%)</p><p><b>Common</b> (1% to 10%): Cough, nasal congestion, pharyngitis</p><p><b>Very rare</b> (less than 0.01%): Change to the sense of smell, dyspnea</p><p><b>Frequency not reported</b>: Upper respiratory tract infection<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Diarrhea occurred most frequently in patients given quadruple therapy (pantoprazole (the active ingredient contained in Protonix)  bismuth, metronidazole, tetracycline) for Helicobacter pylori infections, but was also very common in triple therapy (pantoprazole, amoxicillin, clarithromycin).</p><p></p><p>Nausea, vomiting, abdominal pain, dry mouth, and constipation were more commonly reported in patients given triple therapy, compared to patients given quadruple therapy.</p><p></p><p>Fecal and/or tongue discoloration occurred more commonly in patients given quadruple therapy versus patients given triple therapy.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Diarrhea (Up to 11.6%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, benign fundic gland polyps/fundic gland polyps, buccal inflammation, constipation, dry mouth, dyspepsia, fecal discoloration, flatulence, heartburn, nausea, oral moniliasis, pruritus ani, tongue discoloration, tongue pain, upper abdominal pain, vomiting</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal discomfort/distention, bloating, loose stools</p><p><b>Rare</b> (0.01% to 0.1%): Colon polyp, rectal disorder</p><p><b>Very rare</b> (less than 0.01%): Increased saliva</p><p><b>Frequency not reported</b>: Clostridium difficile-associated diarrhea, severe eructation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Tiredness</p><p><b>Uncommon</b> (0.1% to 1%): Asthenia, fatigue, malaise</p><p><b>Rare</b> (0.01% to 0.1%): Body temperature increased, fever</p><p><b>Very rare</b> (less than 0.01%): Pain, tinnitus</p><p><b>Frequency not reported</b>: Facial edema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Confusion, depression, hallucinations, and disorientation, especially in predisposed patients, occurred with use, and was aggravated in patients with preexisting conditions.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Depression (and all aggravations)</p><p><b>Uncommon</b> (0.1% to 1%): Sleep disorders</p><p><b>Rare</b> (0.01% to 0.1%): Confusion (and all aggravations), disorientation (and all aggravations), hallucination (and all aggravations)</p><p><b>Very rare</b> (less than 0.01%): Anxiety</p><p><b>Postmarketing reports</b>: Insomnia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased liver enzymes (transaminases, GGT)</p><p><b>Rare</b> (0.01% to 0.1%): Increased bilirubin</p><p><b>Very rare</b> (less than 0.01%): Cholestatic hepatitis, hepatitis, hepatocellular failure, jaundice</p><p><b>Frequency not reported</b>: Hepatic effects, hepatocellular injury, liver function tests abnormal</p><p><b>Postmarketing reports</b>: Hepatocellular damage<sup>[Ref]</sup></p><p>Severe hepatocellular damage leading to jaundice/hepatic failure is predicted to have a frequency of 1 in 1,000,000 patients.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Exanthema/exanthemata, rash</p><p><b>Uncommon</b> (0.1% to 1%): Eruption, increased sweating, pruritus</p><p><b>Rare</b> (0.01% to 0.1%): Urticaria</p><p><b>Very rare</b> (less than 0.01%): Erythema multiforme, flushing, Lyell syndrome, photosensitivity/photosensitivity reaction, severe skin reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p><p><b>Frequency not reported</b>: Cutaneous lupus erythematosus, facial edema, fatal skin reactions, fatal TEN, subacute cutaneous lupus erythematosus<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Rare</b> (0.01% to 0.1%): Hypertension, peripheral edema, thrombophlebitis</p><p><b>Very rare</b> (less than 0.01%): Circulatory collapse, flushing, hot flushes, substernal chest pain</p><p><b>Frequency not reported</b>: Generalized edema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Muscle spasm occurred as a consequence of electrolyte disturbances.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Arthralgia</p><p><b>Uncommon</b> (0.1% to 1%): Fracture of the hip/wrist/spine</p><p><b>Rare</b> (0.01% to 0.1%): Myalgia</p><p><b>Very rare</b> (less than 0.01%): Skeletal pain</p><p><b>Frequency not reported</b>: Bone fracture, elevated creatine phosphokinase (CPK)/elevated creatine kinase (CK), muscle spasm, systemic lupus erythematosus</p><p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia</p><p><b>Rare</b> (0.01% to 0.1%): Hyperlipidemia, increased cholesterol, increased triglycerides, lipid increases, weight changes</p><p><b>Frequency not reported</b>: Cyanocobalamin (vitamin B12) deficiency), electrolyte disturbances, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, potential for exacerbation of zinc deficiency<sup>[Ref]</sup></p><p>Hypocalcemia occurred in association with hypomagnesemia.</p><p></p><p>Anorexia commonly occurred in patients with H pylori.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site thrombophlebitis</p><p><b>Frequency not reported</b>: Injection site reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza-like symptoms, moniliasis</p><p><b>Rare</b> (0.01% to 0.1%): Sepsis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic reactions, anaphylactic shock, angioedema/Quincke's edema, hypersensitivity, hypersensitivity reactions</p><p><b>Frequency not reported</b>: Allergic reactions</p><p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, anemia</p><p><b>Very rare</b> (less than 0.01%): Increased coagulation time, leukopenia, pancytopenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Blurred vision, visual disturbances</p><p><b>Very rare</b> (less than 0.01%): Conjunctivitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (0.01% to 0.1%): Gynecomastia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Interstitial nephritis (with possible progression to renal failure)</p><p><b>Frequency not reported</b>: Acute interstitial nephritis<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Protonix I.V. (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. Protonix (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><h2>More about Protonix (pantoprazole)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>74 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: proton pump inhibitors</li>
<li>FDA Alerts (4)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Protonix oral/injection</li>
<li>Protonix &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Protonix Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Protonix IV</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>GERD</li>
<li>Erosive Esophagitis</li>
<li>Barrett's Esophagus</li>
<li>Duodenal Ulcer</li>
<li data-more-config-id="list-data-resources-conditions">... +5 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>